Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective.

Bonate PL, Strougo A, Desai A, Roy M, Yassen A, van der Walt JS, Kaibara A, Tannenbaum S.

AAPS J. 2012 Dec;14(4):749-58. doi: 10.1208/s12248-012-9387-9. Epub 2012 Jul 24. Review.

PMID:
22826033
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes and requirements.

Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Evelhoch J, Hargreaves R, Robertson B, Iyengar S, Tauscher J, Bleakman D, Borsook D.

Drug Discov Today. 2011 Jul;16(13-14):583-93. doi: 10.1016/j.drudis.2011.05.006. Epub 2011 May 24. Review.

PMID:
21635967
[PubMed - indexed for MEDLINE]
3.

The use of population pharmacokinetics in drug development.

Vozeh S, Steimer JL, Rowland M, Morselli P, Mentre F, Balant LP, Aarons L.

Clin Pharmacokinet. 1996 Feb;30(2):81-93. Review.

PMID:
8906893
[PubMed - indexed for MEDLINE]
4.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

PMID:
22058616
[PubMed]
Free PMC Article
5.

Quality control and assurance from the development to the production of biopharmaceuticals.

Doblhoff-Dier O, Bliem R.

Trends Biotechnol. 1999 Jul;17(7):266-70.

PMID:
10370232
[PubMed - indexed for MEDLINE]
6.

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J.

Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. Review.

PMID:
15361314
[PubMed - indexed for MEDLINE]
Free Article
7.

A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices.

Schwarz AJ, Becerra L, Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Evelhoch J, Hargreaves R, Robertson B, Iyengar S, Tauscher J, Bleakman D, Borsook D.

Drug Discov Today. 2011 Aug;16(15-16):671-82. doi: 10.1016/j.drudis.2011.03.011. Epub 2011 Apr 6. Review.

PMID:
21477664
[PubMed - indexed for MEDLINE]
8.

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Jonsson EN, Karlsson MO.

Comput Methods Programs Biomed. 1999 Jan;58(1):51-64.

PMID:
10195646
[PubMed - indexed for MEDLINE]
9.

Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.

Vermes A, Math t RA, van der Sijs IH, Dankert J, Guchelaar HJ.

Ther Drug Monit. 2000 Dec;22(6):676-87.

PMID:
11128235
[PubMed - indexed for MEDLINE]
10.

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD.

Comput Methods Programs Biomed. 2011 Jan;101(1):72-9. doi: 10.1016/j.cmpb.2010.04.018. Epub 2010 Jun 2.

PMID:
20627442
[PubMed - indexed for MEDLINE]
11.

An implementation plan for autopsy quality control and quality assurance.

Young NA, Naryshkin S.

Arch Pathol Lab Med. 1993 May;117(5):531-4.

PMID:
8489345
[PubMed - indexed for MEDLINE]
12.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
[PubMed - indexed for MEDLINE]
Free Article
13.

Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.

Tornøe CW, Agersø H, Jonsson EN, Madsen H, Nielsen HA.

Comput Methods Programs Biomed. 2004 Oct;76(1):31-40.

PMID:
15313540
[PubMed - indexed for MEDLINE]
14.

Evaluation of type I error rates when modeling ordered categorical data in NONMEM.

Wählby U, Matolcsi K, Karlsson MO, Jonsson EN.

J Pharmacokinet Pharmacodyn. 2004 Feb;31(1):61-74.

PMID:
15346852
[PubMed - indexed for MEDLINE]
15.

Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group.

Bromley CM, Close S, Cohen N, Favis R, Fijal B, Gheyas F, Liu W, Lopez-Correa C, Prokop A, Singer JB, Snapir A, Tchelet A, Wang D, Goldstaub D; Industry Pharmacogenomics Working Group.

Pharmacogenomics J. 2009 Feb;9(1):14-22. doi: 10.1038/tpj.2008.11. Epub 2008 Sep 16. Review.

PMID:
18794908
[PubMed - indexed for MEDLINE]
16.

Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.

Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, Wu D, Zhu Y, Wang Y, Chen C.

Eur J Clin Pharmacol. 2013 Jun;69(6):1223-33. doi: 10.1007/s00228-012-1413-4. Epub 2013 Jan 26.

PMID:
23354809
[PubMed - indexed for MEDLINE]
17.

Nonlinearity detection: advantages of nonlinear mixed-effects modeling.

Jonsson EN, Wade JR, Karlsson MO.

AAPS PharmSci. 2000;2(3):E32.

PMID:
11741248
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software.

Farenc C, Fabreguette JR, Bressolle F.

Comput Biomed Res. 2000 Oct;33(5):315-29.

PMID:
11017724
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).

Zannikos PN, Rohatagi S, Jensen BK, DePhillips SL, Rhodes GR.

J Clin Pharmacol. 2000 Oct;40(10):1129-40.

PMID:
11028252
[PubMed - indexed for MEDLINE]
20.

Quality science and quality assurance: observations of an environmental scientist.

Hughes TJ.

Qual Assur. 1999 Oct-Dec;7(4):225-35.

PMID:
11191123
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk